Completed phase 1a dose escalation study of the first oral ENPP1 inhibitor RBS2418 immunotherapy in subjects with metastatic solid tumors.
Thomas U. Marron(Icahn School of Medicine at Mount Sinai), Jamal Misleh(Christiana Care Health System), Aaron J. Scott(University of Arizona), Jordan Berlin(Dana-Farber Cancer Institute), Jennifer Segar(University of Arizona), Alexander I. Spira(Virginia Cancer Specialists), Won Jin Ho(Johns Hopkins University), Deepanwita Sengupta(Veroscience (United States)), Ningwu Huang(University of California, San Francisco), Klaus Klumpp(Veroscience (United States)), Ildiko Csiki(Veroscience (United States)), Jeffrey S. Glenn(Stanford University), Daniel H. Johnson(The University of Texas MD Anderson Cancer Center), Michael S. Gordon(HonorHealth), Juergen Schanzer(Veroscience (United States)), Christopher T. Chen(Palo Alto University), Ralph V. Boccia(Center for Cancer and Blood Disorders), Zev A. Wainberg(University of California, Los Angeles)
Cited by 1
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761